AIM ImmunoTech (AIM) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($7.2 million vs $2.9 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | VIVS |
|---|---|---|
| Share price | $0.1796 | $0.1772 |
| Market cap | $7.17M | $2.94M |
| 1-day change | -1.75% | -7.47% |
| EPS (TTM) | $-3.03 | $-4.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $3.41 |
| 52-week low | $0.17 | $0.17 |
| Distance from 52-week high | -93.57% | -94.80% |
| Analyst consensus | none | — |
| Avg. price target upside | +2266.37% | — |
| Average volume | 4.70M | 5.85M |
| Shares outstanding | 39.89M | 16.59M |
| Employees | 19 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AIM ImmunoTech is about 2.4 times larger than VivoSim Labs by market value ($7.17M vs $2.94M).
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
AIM vs VIVS FAQ
Which is bigger, AIM ImmunoTech or VivoSim Labs?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $7.17M compared with $2.94M for VivoSim Labs (VIVS).
Are AIM ImmunoTech and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.